HPCAIAC
8.4.2020 14:32:09 CEST | Business Wire | Press release
The HPC-AI Advisory Council (HPCAIAC) and the National Supercomputing Centre (NSCC) Singapore announced today that they have joined the global fight against COVID-19 by expanding the 2020 APAC HPC-AI competition to address education and applied learning towards accelerating bioscience research and discovery.
As part of the updated competition, student teams are now tasked to research, find and choose an HPC or AI application that can potentially be used as part of the global fight against COVID-19. Teams must demonstrate testing and benchmarking of the application, as well as explain how this application can best be accelerated. In addition, teams will also be required to focus on tuning and accelerating NAMD, a molecular dynamics code designed for high-performance simulation of large biomolecular systems. The NAMD application is being used at various supercomputing sites to run massive simulations of COVID-19 to aid researchers design new drugs and vaccines to combat the virus.
The APAC HPC-AI competition promotes the latest HPC and AI technologies to the universities and research centers and trains the students with the latest HPC and AI technologies to help bridge the gap between universities/research institutes and industries. The competition also trains the undergraduate and graduate students to practice on the newest HPC and AI platforms, and provides the key ingredients and industry tools to optimize the production applications. Open for registration until May 17, the 3rd Annual 2020 APAC HPC-AI competition expects to host multiple teams from across the APAC region.
“While not ignoring commercial and scientific applications, it has become importantly clear that we must put further emphasis on tuning and optimizing applications in the medical and bioscience field. By expanding the competition’s charter to address applications specifically used for groundbreaking COVID-19 simulations, the HPC-AI Advisory Council and NSCC are taking the action to educate and train the next generation of HPC scientists and programmers that may aid the world in viral outbreaks or pandemics in the future,” said Gilad Shainer, Chairman of the HPC-AI Advisory Council.
"Computer models of viruses and viral protein structures, especially for high resolution analysis, is very computationally intensive. Molecular docking experiments in silico, to screen for potentially effective drugs that block viral functions, and molecular-modeling applications, such as GROMACS and NAMD, must be optimized and benchmarked for simulations to run as efficiently as possible. By training our young aspiring programmers using real-world scenarios such as COVID-19, we can better prepare them to provide solutions to future global issues from pandemics to climate change. More than that, we hope that this will give our youth a better appreciation for the significant role that HPC and AI can play, and how they can use the skills learned in this competition to contribute more meaningfully to society," said Professor Tan Tin Wee, Chief Executive, National Supercomputing Centre (NSCC) Singapore.
Co-organized by the HPC-AI Advisory Council and NSCC, the competition is sponsored by Mellanox, NVIDIA, AMD and WekaIO with additional support from the Singapore Advanced Research and Education Network (SingAREN).
For more information on the 3rd APAC HPC-AI competition and to register teams, please visit the HPC-AI Advisory Council website at http://hpcadvisorycouncil.com/events/2020/APAC-AI-HPC/
About HPC-AI Advisory Council
Founded in 2008, The HPC-AI Advisory Council (HPCAIAC) is a for community benefit organization with over 400 members committed to bridge the gap between high-performance computing and artificial intelligence use and its potential, bringing the beneficial capabilities of HPC and AI to new users for better research, education, innovation and product manufacturing, and brings users the expertise needed to operate HPC and AI systems, provide application designers with the tools needed to enable parallel computing, and to strengthen the qualification and integration of HPC and AI system products. For more information, please visit: www.hpcadvisorycouncil.com .
About National Supercomputing Centre Singapore
The National Supercomputing Centre (NSCC) Singapore was established in 2015 and manages Singapore’s first national petascale facility with available high performance computing (HPC) resources. As a National Research Infrastructure we support the HPC research needs of the public and private sectors, including research institutes, institutes of higher learning, government agencies and companies. With the support of its stakeholders, including Agency for Science Technology and Research (A*STAR), Nanyang Technological University (NTU), National University of Singapore (NUS), Singapore University of Technology and Design (SUTD), National Environment Agency (NEA) and Technology Centre for Offshore and Marine, Singapore (TCOMS), and funded by the National Research Foundation (NRF), NSCC catalyses national research and development initiatives, attracts industrial research collaborations and enhances Singapore’s research capabilities. For more information, please visit https://www.nscc.sg/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005096/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
